Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose hepatitis B vaccine plus pegylated interferon α-2b for functional cure in low HBsAg chronic hepatitis B
ChiCTR2600121635Phase 4Not yet recruiting
- Sponsor
- Xixi Hospital of Hangzhou
- Start
- Apr 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Hepatitis B vaccine and peginterferon alfa-2b in Chronic Hepatitis B (CHB) (4 arms), sponsored by Xixi Hospital of Hangzhou. Primary endpoints: HBsAg clearance rate and Anti-HBs (HBsAb) seroconversion rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Hepatitis B vaccinepeginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2600121635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121635.